CSL Behring has shared positive four-year results from a late-stage study of its haemophilia B gene therapy Hemgenix ...

Just a few months after Vir Biotechnology lost an emergency authorization for its COVID-19 antibody, Marianne de Backer ...

The FDA reviews drug approval decisions that are expected in March 2025. The FDA is reviewing the application for bentracimab for use as a ticagrelor reversal agent in patients with uncontrolled ...

Narrow-moat CSL reiterated fiscal 2025 guidance for constant-currency group net profit after tax before amortization, or NPATA, of USD 3.2 billion to­ USD 3.3 billion, implying 1 ...

I am seeing patients stopping their medication or requesting vitamin drips after hearing about them from health and wellness influencers ...

The global Diabetes Drugs Market size was valued at USD 84.65 billion in 2024 and is expected to be worth around USD 177.74 ...

Equities research analysts at Raymond James lowered their Q4 2026 EPS estimates for Medexus Pharmaceuticals in a report released on Thursday, February 6th. Raymond James analyst M. Freeman now expects ...

“CSL delivered a solid result for the first half of the 2025 financial year led by CSL Behring. Strong demand for many of our market-leading therapies has translated into sales growth, particularly in ...

Boehringer Ingelheim (BI) has announced positive top-line results from a late-stage study of its investigational ...

Our picks of the movies you need to be watching on Netflix in February.